Ramon Villafria
Family Medicine · Longview, TXNPI 1619997319
Payments from drug & device makers
Across 142 payments — averaging $25.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$572
- Novo Nordisk$571
- Johnson & Johnson$368
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$360
- Bayer$344
- Pfizer$326
- plus $1K from 18 others
What the payments were for
- Speaking & faculty fees$1504%
- Food & beverage$3,43295%
- Education$261%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 20 | $572 |
| Novo Nordisk | 26 | $571 |
| Johnson & Johnson | 3 | $368 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 16 | $360 |
| Bayer | 17 | $344 |
| Pfizer | 19 | $326 |
| Amgen | 6 | $228 |
| AbbVie(2 entities) | 6 | $197 |
| Galderma Laboratories, L.p. | 1 | $150 |
| Lilly USA, LLC | 7 | $99 |
| GSK | 5 | $87 |
| Corcept Therapeutics | 2 | $66 |
| Ardelyx, Inc. | 1 | $32 |
| Sumitomo Pharma America, Inc. | 1 | $24 |
| Sunovion Pharmaceuticals Inc. | 2 | $23 |
| Supernus Pharmaceuticals, Inc. | 2 | $23 |
| Cequr Corporation | 1 | $22 |
| SK Life Science, Inc. | 1 | $18 |
| Abbott | 1 | $18 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $18 |
| Dexcom, Inc. | 1 | $17 |
| Exact Sciences | 1 | $16 |
| Xeris Pharmaceuticals, Inc. | 1 | $15 |
| Sanofi-aventis U.S. LLC | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,608 in reported general payments places this provider in the 80th percentile of 8,760 family medicine providers in Texas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 139 | $143,552 |
| FarxigaDapagliflozin Propanediol | 65 | $67,795 |
| TrulicityDulaglutide | 51 | $60,169 |
| EliquisApixaban | 81 | $53,377 |
| JardianceEmpagliflozin | 30 | $35,816 |
| LinzessLinaclotide | 65 | $34,401 |
| MounjaroTirzepatide | 30 | $31,542 |
| JanuviaSitagliptin Phosphate | 18 | $24,244 |
| Dihydroergotamine Mesylate | 11 | $18,999 |
| MyrbetriqMirabegron | 27 | $18,062 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 25 | $16,581 |
| Xigduo XrDapaglifloz Propaned/Metformin | 22 | $9,617 |
| Levemir FlexpenInsulin Detemir | 38 | $6,319 |
| InvokanaCanagliflozin | 11 | $6,230 |
| Breo ElliptaFluticasone/Vilanterol | 13 | $5,847 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $571 | $143,552139 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $99 | $91,71181 claims |
| AstraZenecaFarxiga | $572 | $67,79565 claims |
| PfizerEliquis | $326 | $53,37781 claims |
| AbbVieLinzess | $197 | $34,40165 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $87 | $22,42838 claims |
| Johnson & JohnsonInvokana | $368 | $6,23011 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 8,760 family medicine providers in Texas.
Other family medicine in Longview
- Douglas DenhamSan Antonio$68.5M
- Vicki MillerPasadena$58.3M
- Hareshkumar BogharaDesoto$30.3M
- Earl MartinTomball$30.1M
- Lisa HollowayHouston$30.1M
- William SegerFort Worth$27.5M
- Veronica FragosoHouston$24.5M
- Joel SolisMcAllen$21.1M
- George AtieeSan Antonio$19.9M
- Bonnie ColvilleHouston$19.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.